SCHEMBL438531

SCHEMBL438531

Cc1cc(C(=O)NCC(=O)O)ccc1-c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 2/20 0.59
CTSL P07711 1/20 0.59
PTPN13 Q12923 1/20 0.59
KDM4E B2RXH2 3/20 0.51
HPGD P15428 3/20 0.51
ALDH1A1 P00352 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
USP5 P45974 1/20 0.48
MAPT P10636 1/20 0.47
HIF1A Q16665 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.47
SLC22A8 Q8TCC7 1/20 0.47
MAPK1 P28482 1/20 0.47
ESR2 Q92731 1/20 0.46
TYMS P04818 1/20 0.46
EGFR P00533 1/20 0.46
ROCK2 O75116 2/20 0.46
ROCK1 Q13464 2/20 0.46
GCG P01275 1/20 0.45
SUCNR1 Q9BXA5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL437169 0.87 ALDH1A1 (0.55) PTPRCCTSLPTPN13KDM4EHPGD
SCHEMBL31725067 0.84 PTPRC (0.65) PTPRCCTSLPTPN13KDM4EALDH1A1
SCHEMBL26570869 0.82 PTPRC (0.59) PTPRCCTSLPTPN13KDM4EHPGD
SCHEMBL449165 0.81 MAPK1 (0.61) SMN1; SMN2MAPK1GCG
SCHEMBL7824602 0.81 NR1H4 (0.62) PTPRCCTSLPTPN13KDM4EALDH1A1
SCHEMBL30506282 0.81 NR1H4 (0.62) PTPRCCTSLPTPN13KDM4EALDH1A1
SCHEMBL26118039 0.80 PTPRC (0.88) PTPRCCTSLPTPN13KDM4EHPGD
Methyl Alcohol SCHEMBL6851692 0.78 KDM4E (0.61) KDM4EHPGDALDH1A1SMN1; SMN2MAPT
SCHEMBL16600419 0.78 ROCK1 (0.59) ALDH1A1MAPTMAPK1ROCK2ROCK1
SCHEMBL71847 0.77 KDM4E (0.65) PTPRCCTSLPTPN13KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
US-8716326-B2 Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2014-05-06 US disclosed
US-20120065396-A1 ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 PTPRC 2222/4885CTSL 315/4885PTPN13 3227/4885
US-20120065396-A1 ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME PPIP5K2, SOST, ALPL PTPRC 1949/4885CTSL 2923/4885PTPN13 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.